A Bivalent Omicron-Containing Booster Vaccine against Covid-19Spyros Chalkias, Rituparna Das, Charles Harper et al.|New England Journal of Medicine|2022Cited by 649
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Nelson L. Michael, Leyi Lin et al.|The Lancet|2017Cited by 196
First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)Lindsey R. Baden, Dan H. Barouch, Stephen R. Walsh et al.|The Journal of Infectious Diseases|2012Cited by 168
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trialSpyros Chalkias, Rituparna Das, Frank Eder et al.|Nature Medicine|2022Cited by 144
Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)Dan H. Barouch, Lindsey R. Baden, Jinyan Liu et al.|The Journal of Infectious Diseases|2012Cited by 107